Marshall Wace, LLP Capricor Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding CAPR
# of Institutions
92Shares Held
8.13MCall Options Held
1.78MPut Options Held
1.4M-
Black Rock Inc. New York, NY1.63MShares$29.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.58MShares$28.5 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA638KShares$11.5 Million0.0% of portfolio
-
State Street Corp Boston, MA512KShares$9.27 Million0.0% of portfolio
-
Superstring Capital Management LP New York, NY337KShares$6.1 Million4.49% of portfolio
About CAPRICOR THERAPEUTICS, INC.
- Ticker CAPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,346,200
- Market Cap $440M
- Description
- Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...